A new study suggests that the association between oral contraceptive use and breast cancer risk may depend on how recently the pills were used, as well as their hormonal formulation.
Researchers report that women who had recently used specific types of birth control pills showed a higher likelihood of developing breast cancer compared with those who had never used them or had stopped use earlier.
The findings were published in the journal Cancer Research.
Different formulations under review
In the United States, oral contraceptives are generally available in two main forms. Combined oral contraceptives contain synthetic versions of estrogen and progesterone, while progestin-only pills often referred to as the “mini-pill” contain only a synthetic form of progesterone.
Previous research has long suggested a possible link between hormone exposure and breast cancer risk, given that naturally occurring estrogen and progesterone can influence the growth of certain cancers. However, the extent to which modern contraceptive formulations contribute to that risk has remained unclear.
Increased risk observed among recent users
The research team analyzed data from 1,102 women diagnosed with breast cancer between 1990 and 2009, alongside 21,952 control participants without the disease. Unlike many earlier studies that relied on self-reported contraceptive history, this analysis drew on electronic pharmacy records to improve accuracy.
The results indicated that women who had filled at least one prescription for oral contraceptives within the previous year faced a 50% higher risk of breast cancer compared with former users or those who had never used the pills.
Variation by hormone type and dosage
The study also found that risk levels varied depending on hormone composition and dosage:
- Pills containing higher doses of estrogen were associated with a significantly increased risk.
- Moderate-dose estrogen formulations were linked to a smaller but still elevated risk.
- Low-dose estrogen pills showed no measurable increase in risk.
Certain progestin-containing formulations were also associated with higher risk, including pills containing ethynodiol diacetate and some triphasic combination contraceptives with varying hormone levels across the cycle.
Researchers urge caution in interpretation
While the findings suggest differences in risk across contraceptive types, the authors caution against drawing immediate clinical conclusions.
They noted that the results have not yet been replicated in other studies and emphasized that decisions about contraceptive use should weigh both potential risks and well-established benefits.
Researchers also highlighted that breast cancer remains relatively uncommon in younger women and that previous evidence indicates any elevated risk linked to oral contraceptives tends to decline after discontinuation.
Broader health context
Oral contraceptives are also associated with several protective health benefits, including reduced risk of certain cancers. Earlier research has suggested that use of the pill, along with factors such as breastfeeding and tubal ligation, may lower the risk of ovarian cancer in women with specific genetic mutations, including BRCA1 and BRCA2.
Experts continue to stress that contraceptive choices should be individualized, taking into account personal health history, risk factors, and reproductive goals.
